| pubmed-article:14575704 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:14575704 | lifeskim:mentions | umls-concept:C1456820 | lld:lifeskim |
| pubmed-article:14575704 | lifeskim:mentions | umls-concept:C0017262 | lld:lifeskim |
| pubmed-article:14575704 | lifeskim:mentions | umls-concept:C0851285 | lld:lifeskim |
| pubmed-article:14575704 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:14575704 | pubmed:dateCreated | 2003-10-24 | lld:pubmed |
| pubmed-article:14575704 | pubmed:abstractText | Immunostimulatory activities of synthetic oligodeoxynucleotides containing CpG motifs (CpG-ODNs) have gained attention as potentially useful immunotherapeutics. However, CpG-ODNs induce harmful and lethal shock effects because they greatly enhance the sequence-dependent induction of tumor necrosis factor-alpha (TNF-alpha). We have shown that phosphorothioate-modified oligodeoxynucleotides (PS-ODNs) of the CpG-ODN 1826 stimulate TNF-alpha gene expression, TNF-alpha promoter activity, IkappaB degradation, and NF-kappaB activation at higher levels compared with its phosphodiester ODN (PO-ODN). In contrast to the effects of CpG-ODN 1826, PS-ODN of the CpG-ODN 2006 showed lower stimulatory activities than its PO-ODN. Using transient transfection, it was found that myeloid differentiation protein (MyD88) and tumor necrosis factor receptor-associated factor 6 are commonly required for activation of the TNF-alpha promoter by various CpG-ODNs with different potencies. These results strongly suggest a possibility to optimally activate the innate immune responses by modulating the potency of CpG-ODNs via sequence rearrangement and phosphorothioate backbone modification. | lld:pubmed |
| pubmed-article:14575704 | pubmed:language | eng | lld:pubmed |
| pubmed-article:14575704 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14575704 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:14575704 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14575704 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14575704 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14575704 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14575704 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14575704 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14575704 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14575704 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:14575704 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:14575704 | pubmed:month | Nov | lld:pubmed |
| pubmed-article:14575704 | pubmed:issn | 0006-291X | lld:pubmed |
| pubmed-article:14575704 | pubmed:author | pubmed-author:KimDoo-SikDS | lld:pubmed |
| pubmed-article:14575704 | pubmed:author | pubmed-author:KwonHyung-Joo... | lld:pubmed |
| pubmed-article:14575704 | pubmed:author | pubmed-author:HanJung HoJH | lld:pubmed |
| pubmed-article:14575704 | pubmed:author | pubmed-author:LeeKeun-WookK... | lld:pubmed |
| pubmed-article:14575704 | pubmed:author | pubmed-author:YuSang HoSH | lld:pubmed |
| pubmed-article:14575704 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:14575704 | pubmed:day | 7 | lld:pubmed |
| pubmed-article:14575704 | pubmed:volume | 311 | lld:pubmed |
| pubmed-article:14575704 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:14575704 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:14575704 | pubmed:pagination | 129-38 | lld:pubmed |
| pubmed-article:14575704 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:14575704 | pubmed:meshHeading | pubmed-meshheading:14575704... | lld:pubmed |
| pubmed-article:14575704 | pubmed:meshHeading | pubmed-meshheading:14575704... | lld:pubmed |
| pubmed-article:14575704 | pubmed:meshHeading | pubmed-meshheading:14575704... | lld:pubmed |
| pubmed-article:14575704 | pubmed:meshHeading | pubmed-meshheading:14575704... | lld:pubmed |
| pubmed-article:14575704 | pubmed:meshHeading | pubmed-meshheading:14575704... | lld:pubmed |
| pubmed-article:14575704 | pubmed:meshHeading | pubmed-meshheading:14575704... | lld:pubmed |
| pubmed-article:14575704 | pubmed:meshHeading | pubmed-meshheading:14575704... | lld:pubmed |
| pubmed-article:14575704 | pubmed:meshHeading | pubmed-meshheading:14575704... | lld:pubmed |
| pubmed-article:14575704 | pubmed:meshHeading | pubmed-meshheading:14575704... | lld:pubmed |
| pubmed-article:14575704 | pubmed:meshHeading | pubmed-meshheading:14575704... | lld:pubmed |
| pubmed-article:14575704 | pubmed:meshHeading | pubmed-meshheading:14575704... | lld:pubmed |
| pubmed-article:14575704 | pubmed:meshHeading | pubmed-meshheading:14575704... | lld:pubmed |
| pubmed-article:14575704 | pubmed:meshHeading | pubmed-meshheading:14575704... | lld:pubmed |
| pubmed-article:14575704 | pubmed:meshHeading | pubmed-meshheading:14575704... | lld:pubmed |
| pubmed-article:14575704 | pubmed:year | 2003 | lld:pubmed |
| pubmed-article:14575704 | pubmed:articleTitle | NF-kappaB-dependent regulation of tumor necrosis factor-alpha gene expression by CpG-oligodeoxynucleotides. | lld:pubmed |
| pubmed-article:14575704 | pubmed:affiliation | Institute of Life Science and Biotechnology, Yonsei University, Seoul, Republic of Korea. | lld:pubmed |
| pubmed-article:14575704 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:14575704 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:14575704 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:14575704 | lld:pubmed |
